Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

Scienmag

JANUARY 2, 2022

Mechanical engineer and inventor Zach Lerner, assistant professor in Northern Arizona University’s Department of Mechanical Engineering, has been awarded $2.1 million by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Engineer 79

Engineer Clinical Trials Clinical Trials Trials 79

pharmaphorum

JULY 8, 2022

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. Source: Izmailova et al, 2017.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Regulation 100

pharmaphorum

FEBRUARY 1, 2022

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

Clinical Trials 104

Clinical Trials Clinical Trials Trials Engineer 104

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. TRACTION is a part of the therapeutics discovery division of MD Anderson.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Rethinking Clinical Trials

FEBRUARY 2, 2023

The NIH Pragmatic Trials Collaboratory has developed an online tool to evaluate the complexity of delivery of a trial intervention. A manuscript describing the tool and its development was published today in Contemporary Clinical Trials. The tool is free to use and available online.

Development 130

Development Clinical Trials Clinical Trials Trials 130

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 19, 2024

Different types of brain cells could age at different speeds, and that may help explain the development of Alzheimer’s disease.

Engineer 202

Engineer Development Clinical Trials Clinical Trials 202

Pharmaceutical Technology

AUGUST 11, 2022

GentiBio and Bristol Myers Squibb (BMS) have signed a multi-year partnership agreement for developing new engineered Treg therapies for inflammatory bowel disease (IBD) patients. These therapies will be developed for re-instating immune tolerance and repairing tissue in IBD.

Development 130

Development Engineer Gene Therapy Clinical Trials 130

Pharmaceutical Technology

OCTOBER 26, 2022

According to Tufts Center for the Study of Drug Development (CSDD), in a typical Phase Ill clinical trial, 119 protocol deviations are implemented on average, involving approximately one-third of all patients participating in that trial. IRT standardisation leads to increased consistency and quality.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Production 130

Pharmaceutical Technology

APRIL 20, 2023

The funds will support Maxion’s KnotBody platform to develop antibodies to treat autoimmune diseases. As per the company, this allows for a longer half-life in the body and gives the ability for further biomolecular engineering. As per Maxion, there are more than 80 types of autoimmune conditions.

Development 130

Development Antibody Engineer Clinical Trials 130

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 27, 2022

The Indian Institute of Science (IISc) researchers from the Centre for Nano Science and Engineering (CeNSE) have developed fabricated pressure sensors that use paper as the medium which find applications in healthcare. This is because medical treatments depend considerably on accurate and precise measurement of pressure.

Development 100

Development Research Engineer Clinical Trials 100

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. These viruses are engineered genetically for killing cancer. The post City of Hope researchers develop new brain cancer therapy appeared first on Pharmaceutical Technology.

Development 130

Development Research Antibody Engineer 130

pharmaphorum

APRIL 11, 2022

Dudley Tabakin, CEO of VivoSense, describes how this financing is set to accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense software is developed specifically for analysis of data from wearable sensors”, explains Tabakin. Searching for the right solution.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Development 111

Scienmag

JUNE 23, 2021

Credit: University of Leeds Digital trial replicated and expanded upon results of traditional clinical trials Developing virtual patient populations can speed up trials process A study involving virtual rather than real patients was as effective as traditional clinical trials in evaluating a medical device used to treat brain aneurysms, according to (..)

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

Pharmaceutical Technology

JUNE 12, 2023

Quell Therapeutics and AstraZeneca have entered a collaboration, exclusive option and licence deal for the development, manufacturing and commercialisation of engineered T-regulator (Treg) cell therapies for autoimmune diseases. AstraZeneca will make an upfront payment to Quell of $85m, mostly in cash.

Engineer 130

Engineer Gene Therapy Clinical Trials Clinical Trials 130

Scienmag

JUNE 14, 2021

Investments have catalyzed research, clinical trials and revolutionary treatments across many disciplines UC San Francisco is launching a new initiative to propel the development of living therapeutics – a category of treatments broadly defined as human and microbial living cells that are selected, modified, or engineered to treat or cure disease (..)

Development 75

Development Engineer Clinical Trials Clinical Trials 75

Drug Discovery World

OCTOBER 10, 2023

The grant is intended to support the entire trajectory of drug development – from the proof-of-concept studies through to the IND-enabling studies required for a clinical trial and the Phase I/II clinical trial for both diseases.

Gene Editing 52

Gene Editing Development Drugs Clinical Trials 52

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Licensing Licensing 264

Drug Discovery World

FEBRUARY 2, 2024

Head of clinical trials at the University College London (UCL) Dementia Research Centre, Dr Cath Mummery, has been announced as the Director of a new network of dementia trial sites across the country. million of new funding to improve access to clinical trials and help accelerate the development of new treatments.

Research 100

Research Clinical Trials Clinical Trials Trials 100

pharmaphorum

SEPTEMBER 16, 2022

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas.

Development 135

Development Research Drugs Clinical Trials 135

Pharmaceutical Technology

NOVEMBER 29, 2022

Focus-X works on developing targeted radiopharmaceuticals based on peptide engineering technology for treating cancer. According to the deal, Focus-X shareholders are entitled to receive an upfront payment, potential development, and regulatory and sales-based milestones of up to $245m, in addition to royalties on any commercial sales.

Sales 147

Sales Engineer DNA Clinical Trials 147

Pharmaceutical Technology

JUNE 24, 2022

The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 65

Development Research Drugs Antibody 65

Pharmaceutical Technology

AUGUST 12, 2022

The latest approval was based on the findings from the Phase II DESTINY-Lung02 clinical trial, which assessed the safety and efficacy of two doses of Enhertu in HER2 mutant metastatic NSCLC patients. . In the trial, 1.9% According to the interim efficacy data from a pre-specified patient cohort, a 5.4

FDA Approval 264

FDA Approval Clinical Trials Clinical Trials Engineer 264

Drug Discovery World

MAY 21, 2024

Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These generative models will create a small, highly confident group of candidates with high binding efficacy and developability.

Antibody 59

Antibody Development FDA Approval Contract Manufacturing 59

Pharmaceutical Technology

APRIL 26, 2023

INB-400, an autologous, genetically engineered gamma-delta T cell therapy, is the company’s DeltEx chemotherapy-resistant autologous and allogeneic drug-resistant immunotherapy (DRI) technology. This marks the first-ever designation for genetically modified gamma-delta T cell therapies.

Genetic Engineering 130

Genetic Engineering Drugs Genetics Engineer 130

Drug Discovery World

DECEMBER 19, 2022

Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. . The post Partnership to co-develop cell therapy for multiple myeloma appeared first on Drug Discovery World (DDW).

Development 52

Development Engineer Clinical Trials Clinical Trials 52

Pharmaceutical Technology

APRIL 11, 2023

The finding was made as part of a study published in the journal Nature Biomedical Engineering. Kelley added: “Engineering-based tools allow you to do things that open up new areas of biology. Kelley founded a new health tech startup, CTRL Therapeutics, which has secured seed financing worth $10m in a separate development.

Scientist 244

Scientist Engineer Clinical Trials Clinical Trials 244

STAT News

NOVEMBER 15, 2022

As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government.

Vaccination 145

Vaccination Vaccine Engineer Clinical Trials 145

Pharmaceutical Technology

JANUARY 13, 2023

Being co-developed and co-marketed by Daiichi Sankyo along with AstraZeneca , Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC). Enhertu’s safety profile was consistent with the previous clinical trials.

HR 321

HR Trials Engineer Clinical Trials 321

STAT News

JULY 11, 2022

Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition. Read the rest…

Gene 111

Gene Gene Therapy Genetic Engineering Engineer 111

Cloudbyz

MAY 4, 2022

NAPERVILLE, Ill. , May 4, 2022 /PRNewswire/– Cloudbyz , a fast-growing integrated clinical research and development solution provider with integrated capabilities, today announced that it has partnered with Tech Mahindra to provide integrated Clinical Trial Management Solutions.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

Scienmag

JUNE 2, 2022

The app, called neoSCB, was developed by clinicians and engineers at UCL […].

Clinical Trials 63

Clinical Trials Clinical Trials Engineer Trials 63

The Pharma Data

MARCH 18, 2022

Columbia Engineering researchers report that they have developed a “cloaking” system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells in mice. Sheng Professor of Biomedical Engineering. ” An Effective On/Off Switch.

Bacteria 52

Bacteria Engineer Drugs Research 52